Topic 442: quantitative traceable reference materials as mddts for tissue biomarkers
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00032
- Awardee
-
Boston Cell Standards Inc. UEI HA17F32KXEV8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $385,889
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $385,889.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 8 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Sharon, MA 02067, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $385,889 |
About this award
This $385,889 firm fixed price Phase I SBIR contract was awarded by the National Cancer Institute (NCI) to Boston Cell Standards Inc., a for-profit manufacturer of medical devices, diagnostics, and related services. Boston Cell Standards was selected under a small business set-aside to develop quantitative traceable reference materials as medical device development tools for tissue biomarkers in cancer detection. Through this prime contract, Boston Cell Standards will support NCI's cancer research and diagnostics mission. The company has previously received over $5.1 million in NCI grant funding to establish the National Immunohistochemistry Standardization Program, which aims to improve laboratory testing standards and reduce analytic errors for cancer diagnosis and treatment.
Quick answers
Who was awarded contract 75N91022C00032?
75N91022C00032 was awarded to Boston Cell Standards Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2022.
How much is contract 75N91022C00032 worth?
The government has obligated $385,889 on 75N91022C00032.
Was contract 75N91022C00032 competed?
The extent of competition for 75N91022C00032 was full and open competition after exclusion of sources. The government received 8 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award